Pfizer Inc. (NYSE:PFE) Stock Position Lowered by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG lowered its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 15.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 384,264 shares of the biopharmaceutical company's stock after selling 69,227 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in Pfizer were worth $10,195,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. PSI Advisors LLC boosted its position in shares of Pfizer by 1.4% in the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after buying an additional 385 shares during the period. Patriot Financial Group Insurance Agency LLC grew its position in Pfizer by 1.0% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock valued at $1,027,000 after acquiring an additional 391 shares in the last quarter. D Orazio & Associates Inc. raised its stake in shares of Pfizer by 5.5% during the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock valued at $200,000 after purchasing an additional 391 shares during the period. Lipe & Dalton lifted its position in shares of Pfizer by 17.7% during the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 400 shares in the last quarter. Finally, Oliver Luxxe Assets LLC boosted its stake in shares of Pfizer by 2.2% in the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock valued at $499,000 after purchasing an additional 401 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Remove Ads

Pfizer Stock Performance

Pfizer stock traded down $0.82 during midday trading on Tuesday, reaching $24.53. 54,333,514 shares of the stock traded hands, compared to its average volume of 39,206,025. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $139.09 billion, a price-to-earnings ratio of 17.39, a PEG ratio of 0.64 and a beta of 0.61. The firm has a fifty day moving average price of $26.05 and a two-hundred day moving average price of $26.88.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.10 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Truist Financial cut their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. Citigroup cut their price target on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Bank of America restated a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. UBS Group reduced their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. Finally, Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.06% of the company's stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.